Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism

Author:

Patterson Sarah C.1ORCID,Pomeroy Amy E.1ORCID,Palmer Adam C.1ORCID

Affiliation:

1. Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Abstract

Abstract Most aggressive lymphomas are treated with combination chemotherapy, commonly as multiple cycles of concurrent drug administration. Concurrent administration is in theory optimal when combination therapies have synergistic (more than additive) drug interactions. We investigated pharmacodynamic interactions in the standard 4-drug “CHOP” regimen in peripheral T-cell lymphoma (PTCL) cell lines and found that CHOP consistently exhibits antagonism and not synergy. We tested whether staggered treatment schedules could improve tumor cell kill by avoiding antagonism, using in vitro models of concurrent or staggered treatments. Surprisingly, we observed that tumor cell kill is maximized by concurrent drug administration despite antagonistic drug–drug interactions. We propose that an ultrasensitive dose response, as described in radiology by the linear–quadratic (LQ) model, can reconcile these seemingly contradictory experimental observations. The LQ model describes the relationship between cell survival and dose, and in radiology has identified scenarios favoring hypofractionated radiotherapy—the administration of fewer large doses rather than multiple smaller doses. Specifically, hypofractionated treatment can be favored when cells require an accumulation of DNA damage, rather than a “single hit,” to die. By adapting the LQ model to combination chemotherapy and accounting for tumor heterogeneity, we find that tumor cell kill is maximized by concurrent administration of multiple drugs, even when chemotherapies have antagonistic interactions. Thus, our study identifies a new mechanism by which combination chemotherapy can be clinically beneficial that is not contingent on positive drug–drug interactions.

Funder

V Foundation for Cancer Research

National Institute of General Medical Sciences

Publisher

American Association for Cancer Research (AACR)

Reference50 articles.

1. Non-hodgkin lymphoma: diagnosis and treatment;Ansell;Mayo Clin Proc,2015

2. Brentuximab vedotin in the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma;Shea;Curr Hematol Malig Rep,2020

3. Drug Formulary Database : CHOP. Ontario (Canada): Cancer Care Ontario. [updated 2019 July 1

4. cited 2022 July 26]. https://www.cancercareontario.ca/en/drugformulary/regimens/45796.

5. Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer;Pitman;Semin Oncol,1983

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3